CVS Health Revenue surpasses $100B as integrated care model drives growth

CVS Health (NYSE:CVS) delivered a strong start to fiscal 2026, surpassing the $100 billion quarterly revenue threshold as its diversified healthcare services model captured increased demand across pharmacy and insurance channels.

The Woonsocket, Rhode Island-based healthcare giant reported a 6.2% year-over-year increase in total revenue, reaching $100.4 billion for the quarter ended March 31, 2026.

The company’s profitability remained robust despite ongoing pressure in the broader healthcare reimbursement landscape.

GAAP diluted earnings per share (EPS) for the quarter was $2.30, while adjusted EPS—which excludes amortization of intangible assets and other one-time items—came in at $2.57.

The Health Care Benefits segment, which includes Aetna, showed significant stabilization.

The Medical Benefit Ratio (MBR)—a key metric representing the percentage of premiums spent on healthcare claims—improved to 84.6%.

This margin expansion suggests a successful navigation of medical cost trends, particularly within the Medicare Advantage and commercial populations.

The Health Services segment continued its growth trajectory, with revenue rising to $48.2 billion.

Growth was supported by the company’s pharmacy benefit management (PBM) services and its expanding network of primary care and clinical providers.

Meanwhile, the Pharmacy & Consumer Wellness segment saw strong utilization, with total prescriptions processed rising to 451.2 million (on a 30-day equivalent basis), reflecting high consumer loyalty and the essential nature of its retail footprint.

Buoyed by the first-quarter performance and improved visibility into medical cost trends, CVS Health management raised its full-year 2026 financial guidance

While GAAP EPS is now expected in the range of $6.24 to $6.44, adjusted EPS has been raised to a range of $7.30 to $7.50.